113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000692-32-IT17/07/201914/01/2020Trial to evaluate the efficacy of the drug metformin on the muscles in patients with myotonic distrophy type 1 EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial. - MetMyd Myotonic Distrophy type 1, confirmed by genetic testing, with a CTG expansion size >100
MedDRA version: 20.0 Level: PT Classification code 10068871 Term: Myotonic dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0 Level: LLT Classification code 10013987 Term: Dystrophia myotonica System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATANULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
194 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noItaly
2NCT01995032October 201320/11/2013L-citrulline and Metformin in Duchenne's Muscular DystrophyA Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular DystrophyDuchenne's Muscular Dystrophy (DMD)Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.;Drug: PlaceboUniversity Hospital, Basel, SwitzerlandNULLCompleted78 Months10 YearsAll47Phase 3Switzerland
3EUCTR2013-001732-21-FR06/09/201318/02/2014A phase II study of metformin in myotonic dystrophy type 1 patientsA randomized, double blind, placebo-controlled phase II study of metformin in myotonic dystrophy type 1 patients - Myomet Myotonic dystrophy type 1 (DM1) also known as Steinert disease;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: metformin 500mg
INN or Proposed INN: METFORMIN
Centre d'Etude des Cellules Souches (CECS)NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France
4NCT02018731June 201317/12/2013L-citrulline and Metformin in Becker's Muscular DystrophyPilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular DystrophyBecker's Muscular Dystrophy (BMD)Drug: Metformin and Metformin & L-Citrulline;Drug: L-Citrulline and Metformin & L-CitrullineUniversity Hospital, Basel, SwitzerlandNULLCompleted18 YearsN/ABoth20Phase 2Switzerland
5NCT02516085January 20123/8/2015Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and MetforminDuchenne Muscular DystrophyDrug: Metformin;Drug: L-ArginineUniversity Hospital, Basel, SwitzerlandNULLCompleted7 Years10 YearsBoth5Phase 1NULL